Azithromycin controlled-release microspheres - Pfizer

Drug Profile

Azithromycin controlled-release microspheres - Pfizer

Alternative Names: Azithromycin dihydrate microspheres for oral suspension - Pfizer; Azithromycin extended release - Pfizer; Azithromycin SR (2g single dose) - Pfizer; Sustained-release azithromycin - Pfizer; Zmax; Zmax for oral suspension; Zmax SR

Latest Information Update: 12 Aug 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Pfizer
  • Class Antibacterials; Eye disorder therapies; Macrolides; Small molecules
  • Mechanism of Action Protein 50S ribosomal subunit inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Acute exacerbations of chronic bronchitis; Acute sinusitis; Community-acquired pneumonia; Pharyngitis; Respiratory tract infections; Tonsillitis
  • Discontinued Otitis media

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 12 Aug 2015 No recent reports on development identified - Phase-III for Community-acquired pneumonia in Japan (PO)
  • 29 Oct 2010 Launched for Acute exacerbations of chronic bronchitis in Canada (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top